Dr. Fraser is a Professor and Clinician Scientist in Critical Care/Trauma Medicine at Western University and Lawson Health Research Institute. With the emergence of SARS-CoV-2 (COVID-19), Dr. Fraser and his team quickly expanded their research capabilities to better understand this new threat to human health. With a growing number of SARS-CoV-2 peer-reviewed publications, 4 provisional patents and numerous media features, Dr. Fraser has become the authority on COVID19 diagnostics, prognostics and pathophysiology. In particular, Dr. Fraser and his team have profiled critically ill SARS-CoV-2 (COVID19) subjects for changes in their transcriptiome, metabolome and proteome, with specific emphasis on understanding the immune response. Dr. Fraser received his MD/PhD in Physiology and Biophysics at the University of Calgary (Alberta, Canada). He was the recipient of numerous Pre- and Post-Doctoral research awards from the Medical Research Council as well as other agencies. He subsequently completed his Medical Residency at Queen’s University, and then he received clinical fellowship training at the University of Ottawa in Critical Care Medicine. Dr. Fraser has received prestigious international training research awards, as well as a Canadian Institutes of Health Research (CIHR) Strategic Training Fellowship. He is a Fellow of the Royal College of Physicians and Surgeons of Canada. He has received multiple Innovation Awards and he was recently recognized as a ‘Scientist of the Year’. He is a Founder and Chief Medical Officer of NeuroLytixs, Inc., a diagnostics-based biotech company.